Filing Flows › Fennec Pharmaceuticals (FENC) › Q1 2026
Fennec Pharmaceuticals (FENC) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Fennec Pharmaceuticals (FENC) reported revenue of $15.1M for the first quarter 2026 (Q1 2026), +73% from a year earlier and +10% from the quarter before. Operating margin was -0.8%, net earnings $201K (1.3% of revenue).
Fennec Pharmaceuticals, Q1 2026: revenue $15.1M (+73% year over year), operating margin -0.8%, net earnings $201K, operating cash flow $2.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.1M | +10% | +73% |
| Operating profit | −$119K | — | — |
| Net earnings | $201K | — | — |
| Operating cash flow | $2.4M | — | — |
What changed
Revenue was $15.1M in Q1 2026, up 73% year over year and up 10% from the previous quarter.
Operating costs exceeded revenue by $119K, an operating margin of -0.8%. Total costs grew 59% against revenue growth of 73%. The fastest-growing cost line was Sales & marketing (+254%). Net earnings were $201K. The effective tax rate was 0.0%. Non-operating items added $320K, 159% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $2.4M, 1184% of net earnings. Non-cash charges added back $1.0M of share-based compensation. Working capital and other items added $1.2M.
Questions
What was Fennec Pharmaceuticals' revenue in the first quarter 2026?
Fennec Pharmaceuticals (FENC) reported revenue of $15.1M for the first quarter 2026 (Q1 2026), +73% from a year earlier and +10% from the quarter before.
Was Fennec Pharmaceuticals profitable in the first quarter 2026?
Operating loss was $119K (-0.8% of revenue) and net earnings $201K.